MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from issuance ofcommon stock in...$230,000K Proceeds from exercise ofstock options$956K Net cash provided by(used in) financing...$214,731K Canceled cashflow$16,225K Net increase(decrease) in cash and cash...$148,412K Canceled cashflow$66,319K Payment of financingcost in connection...$14,247K Payment of contingentvalue right liability$1,978K Stock-based compensation$3,376K Non-cash interestexpense - royalty...$2,039K Accounts payable$851K Change in fair value ofderivative liabilities -...$116K Non-cash lease operatingexpense$44K Net cash used ininvesting activities-$55,440K Net cash used inoperating activities-$10,864K Effect of exchange ratechange on cash and cash...-$15K Canceled cashflow$6,426K Purchase of marketablesecurities$55,440K Net loss-$15,767K Accrued expenses andother current...-$900K Prepaid expenses andother current assets$357K Change in fair value ofderivative liabilities -...-$202K Payments on operatinglease liabilities-$49K Accretion on marketablesecurities$15K
Cash Flow

PALVELLA THERAPEUTICS, INC. (PVLA)

PALVELLA THERAPEUTICS, INC. (PVLA)

source: myfinsight.com